News

As per the development collaboration, Activaero’s FAVORITE (Flow and Volume Controlled Inhalation Technology) inhalation approach will be used along with an undisclosed compound to treat PH. The program

The study will assess the safety and efficacy profile of a once-daily oral combination regimen comprising Bristol-Myers’ investigational NS5A replication complex inhibitor daclatasvir and Merck’s investigational NS3/4A protease

As per the agreement, Phyto Nutricare will pay a one-time license fee of $2m to Plandai and then a recurring payment of 5% from the future profits of

As per the agreement, DSM will initiate the development activities for DecImmune’s lead monoclonal antibody program. DecImmune is developing an antibody-based therapeutic that can prevent tissue damage and

The DSM plant was built with the cooperation of the Queensland and Commonwealth Governments of Australia. DSM Biologics president Karen King said that the company’s partnership with the

MINASTRIN 24 FE (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) is indicated for use by females of reproductive age for the prevention of pregnancy. A

The extension of the collaboration that was initiated in May 2010 further validates Evotec’s technology platform, according to the company. Evotec chief operating officer Dr Mario Polywka said,

Accurin that leverages BIND’s Medicinal Nanoengineering platform has superior target selectivity and the potential to improve outcomes in patients with oncology, inflammatory diseases and cardiovascular disorders. BIND president

The Trial Interactive PSMF technology is compliant with the legal requirements as outlined in the Commission Implementing Regulation and as detailed in GVP Module II. TransPerfect will offer